Vicki Bryan, Senior Analyst, High Yield, Gimme Credit
Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/1/15 and contains information from public web pages and contributions from the ZoomInfo community.
User Verified.

Senior Analyst, High Yield

Gimme Credit
17 State Street
New York , New York 10004
United States

Company Description: Gimme Credit is a leading independent provider of corporate bond research for institutional investors. Our reports are read daily by major institutional bond...   more

Employment History

196 Total References
Web References
Gimme Credit's Vicki ..., 1 April 2015 [cached]
Gimme Credit's Vicki Bryan was quoted in the story projecting Pilgrims will have $720 million of free cash flow available for acquisitions, with room to increase debt, which would put Sanderson, valued at $1.8 billion and Oaktree Capital's AdvancePierre, for sale for approximately the same amount, within financial reach.
But Vicki Bryan of ..., 11 Mar 2015 [cached]
But Vicki Bryan of Gimme Credit said Valeant might be stretched to meet Endo's "very credible offer."
Gimme Credit, 24 Jan 2015 [cached]
Airlines: Vicki Bryan
Building Products: Vicki Bryan
Food: Vicki Bryan
Healthcare: Vicki Bryan
Homebuilding: Vicki Bryan
Industrials: Vicki Bryan
Transportation: Vicki Bryan
Bryan earned her M.S. in finance from University of Houston, where she also was an adjunct professor.
Vicki Bryan, senior high ..., 16 June 2014 [cached]
Vicki Bryan, senior high yield analyst, Gimme Credit, told Bloomberg reporters, for a May 27 article: "Valeant's strategy depends on people continuing to drink this Kool Aid it's serving. ...
Vicki Bryan
Vicki Bryan of Gimme ..., 17 Nov 2014 [cached]
Vicki Bryan of Gimme Credit said the often nasty battle for Allergan has exposed questions about Valeant's business model that could haunt efforts to land future large deals.
"The problematic part of their story persists and the main thrust of their highly touted business strategy to buy their way to victory continues to lose credibility," she said in an interview.
In addition to concerns about the quality of Valeant's core operating trends, Bryan said Valeant faces lawsuits and regulator probes on alleged insider trading in Allergan.
"I am skeptical on their prospects," she said, adding that Valeant may have trouble financing a takeover of a company with a lesser quality than Allergan.
Allergan was attractive for Valeant primarily because of its eye care and Botox lines, along with more than US$4 billion in cash.
Valeant's next targets are likely going to be much smaller and not as well-respected, Bryan said.
Other People with the name "Bryan":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.